



June 29, 2022

The General Manager

Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi

Dear Sir,

Sub: Disclosure of Price Sensitive Information – Proposed Investment in sanofi-aventis Pakistan Limited (Company)

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 of the Rule Book issued by the Pakistan Stock Exchange Limited ("PSX"), this is in continuation of our earlier letter dated May 6, 2022, in which we informed that Sanofi Foreign Participations B.V. ("Sanofi") and an investor consortium comprised of Packages Limited, IGI Investments (Private) Limited and affiliates of Arshad Ali Gohar Group, and being led by Packages Limited (collectively, the "Consortium") have executed a binding Share Purchase Agreement for the sale by Sanofi to the Consortium of all 52.87% shares held by Sanofi in the Company (the "Transaction").

Please note that in connection with the Transaction a Public Announcement of Offer was made by Arif Habib Limited (Manager to the Offer) on June 28, 2022 regarding mandatory public offer in accordance with the provisions of Part IX of the Securities Act 2015 and Listed Companies (Substantial Acquisition of Voting Shares and Takeovers) Regulations 2017.

Completion of the above mandatory public offer is one of the conditions to closing of the Transaction. Closing of the Transaction is also subject to other customary closing conditions, including relevant approvals by regulatory authorities, and approval by the shareholders of the Company of certain Transaction related matters.

A disclosure form as required under S.R.O. 143/(1)/2012 dated December 5, 2012 read with Sections 96 and 131 of the Securities Act, 2015 is also enclosed as an Annexure hereto.

You are requested to disseminate the information to the Members of the Exchange accordingly.

Yours sincerely,

Muhammad Abu Bakar Siddiq
Company Secretary
Encl: As above

- Cc: (i) **Executive Director/HOD**, Offsite-II Department, Supervision Division, Securities & Exchange Commission of Pakistan, 63, NIC Building, Jinnah Avenue, Blue Area, Islamabad
(ii) **Director/HOD**, Company Law Division, Securities & Exchange Commission of Pakistan, NIC Building, Jinnah Avenue, Blue Area, Islamabad; and
(iii) **Company Registration Office**, Securities & Exchange Commission of Pakistan, 4th Floor, State Life Building No. 2, Wallace Road, Karachi

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk



SANOFI

DISCLOSURE FORM INTERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015

Name of Company	sanofi-aventis Pakistan Limited
Date of Report	June 29, 2022
Name of Company as specified in The Memorandum	sanofi-aventis Pakistan Limited
Company's Registered Office	Plot No. 23, Sector-22, Korangi Industrial Area, Karachi
Contact Information	Tel: +92 21 35060221-35

Disclosure of price sensitive / inside information by listed company in terms of Section 96 and 131:

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 of the Rule Book issued by the Pakistan Stock Exchange Limited ("**PSX**"), this is in continuation of our earlier letter dated May 6, 2022, in which we informed that Sanofi Foreign Participations B.V. ("Sanofi") and an investor consortium comprised of Packages Limited, IGI Investments (Private) Limited and affiliates of Arshad Ali Gohar Group, and being led by Packages Limited (collectively, the "Consortium") have executed a binding Share Purchase Agreement for the sale by Sanofi to the Consortium of all 52.87% shares held by Sanofi in the Company (the "Transaction").

Please note that in connection with the Transaction a Public Announcement of Offer was made by Arif Habib Limited (Manager to the Offer) on June 28, 2022 regarding mandatory public offer in accordance with the provisions of Part IX of the Securities Act 2015 and Listed Companies (Substantial Acquisition of Voting Shares and Takeovers) Regulations 2017.

Completion of the above mandatory public offer is one of the conditions to closing of the Transaction. Closing of the Transaction is also subject to other customary closing conditions, including relevant approvals by regulatory authorities, and approval by the shareholders of the Company of certain Transaction related matters.

Pursuant to the requirements of the Securities Act, 2015, the Company has duly caused this form/statement to be signed on its behalf by the undersigned hereunto duly authorized.

Intimation of decision of the listed company to delay disclosure of inside information in terms of Section 96(4).

NIL

Disclosure of inside information by listed company where the listed company or person acting on its behalf discloses inside information to third party in terms of Section 131.

NIL

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk



Disclosure of transactions conducted by persons discharging managerial responsibilities within a listed company or persons closely associated with them.

NIL

For and on behalf of
sanofi-aventis Pakistan Limited

Muhammad Abu Bakar Siddiq
Company Secretary

sanofi-aventis Pakistan limited

Plot No. 23, Sector No. 22, Korangi Industrial Area, Karachi-74900, Pakistan
PABX: +92-21-35060221-35 Fax: +92-21-35060358 Web: sanofi.com.pk